Current Report Filing (8-k)
18 October 2017 - 7:19AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 12, 2017
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-37428
|
26-3474527
|
(State
or other
jurisdiction
of incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
1880
Century Park East, Suite 1000
|
|
|
Los
Angeles, California
|
|
90067
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02.
|
Departure
of Directors or Certain Officers; Selection of Directors; Appointment of Certain Officers; Compensating Arrangements of Certain
Officers
|
On
October 12, 2017, Ritter Pharmaceuticals, Inc. (the “Company”) appointed Jeffrey Benjamin the Company’s new
Vice President, Finance, effective October 16, 2017. Following the Company’s filing of its quarterly report on Form 10-Q
for the third quarter of fiscal year 2017, which is expected to be filed on or about October 31, 2017, Mr. Benjamin will serve
as the Company’s principal financial officer and principal accounting officer. Until such time, Ellen Mochizuki, the Company’s
former Vice President, Finance, who has agreed to provide consulting services to the Company to ensure an orderly transition,
will continue to act as the Company’s principal financial officer and principal accounting officer.
Mr.
Benjamin, 52, previously served as Interim Corporate Controller for Unified Grocers (acquired by Supervalu Inc. in June 2017)
since February 2017. Prior to that he served as a principal consultant for Tatum Consulting from January 2015 to January 2017,
Chief Financial Officer of Communications Infrastructure Corporation from March 2013 to January 2015, and Corporate Controller
of Liaison Technologies, Inc. from April 2012 to March 2013.
Mr.
Benjamin will receive an initial annual base salary of $175,000 and will be eligible to earn an annual bonus of up to 20% of his
base salary, in the board of director’s sole discretion. Mr. Benjamin will also be eligible to receive all other benefits
that the Company makes available to its employees generally.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
RITTER
PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/
Michael D. Step
|
|
|
Name:
|
Michael
D. Step
|
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
Date:
|
October
17, 2017
|
|
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2024 to May 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Ritter Pharmaceuticals Inc (NASDAQ): 0 recent articles
More Ritter Pharmaceuticals Inc News Articles